

1 Supplementary Appendix for “Alternative dosing
2 regimens of GLP-1 receptor agonists may reduce
3 costs and maintain efficacy”

4 Anıl Cengiz* Calvin C. Wu, M.D.[†] Sean D. Lawley, Ph.D.[‡]

5 November 27, 2024

6 **Contents**

7	S.1PKPD models	2
8	S.1.1 Semaglutide PK	2
9	S.1.2 Tirzepatide PK	2
10	S.1.3 Semaglutide PD	3
11	S.1.3.1 Semaglutide E_{\max} values	4
12	S.1.4 Tirzepatide PD	6
13	S.1.5 Semaglutide average versus time-dependent concentration	6
14	S.2BMI and mortality calculations	7

*Department of Mathematics, University of Utah, Salt Lake City, UT 84112 USA.

[†]Tono Health, 90 Furman St. N801, Brooklyn, NY 11201, United States

[‡]Department of Mathematics, University of Utah, Salt Lake City, UT 84112 USA
(lawley@math.utah.edu).

15 This Supplementary Appendix details the methods used in the main text.
 16 The computer code which implements the model and creates the relevant figures
 17 is publicly available at <https://github.com/seanlawley/glp1>.

18 S.1 PKPD models

19 We now present the pharmacokinetic (PK) and pharmacodynamic (PD) models
 20 of semaglutide and tirzepatide used in this paper. To briefly summarize, our
 21 semaglutide PK and PD models are from Strathe et al. [1]. The semaglutide
 22 parameters for our “average” virtual patient are taken from Table S2A for PK
 23 and Table S3 for PD in the supplementary information of Ref. [1] (except for
 24 certain “ E_{\max} ” values, see section S.1.3.1 below). We model tirzepatide PK with
 25 the model and parameters of [2], and we use the data of Jastreboff et al. [3] to
 26 reparameterize the semaglutide PD model of [1] to model tizepatide PD.

27 S.1.1 Semaglutide PK

28 Following [1], we model the semaglutide concentration at time $t \geq 0$, denoted
 29 $C(t)$, using a one-compartment model,

$$\frac{dC}{dt} = -k_e C + k_a \frac{DF}{V} \sum_{n=0}^{\lfloor t/\tau \rfloor} e^{-k_a(t-n\tau)}, \quad (\text{S.1})$$

30 where k_a and k_e are the respective first-order absorption and elimination rates,
 31 D is the dose size, $F \in (0, 1]$ is the bioavailability, V is the volume of distribution,
 32 τ is the dosing interval, and $\lfloor t/\tau \rfloor$ denotes the largest integer less than or equal
 33 to t/τ . The semaglutide PK parameter values from [1] are given in Table S.1.

34 S.1.2 Tirzepatide PK

35 Following [2], we model the tirzepatide concentration using a two-compartment
 36 model,

$$\begin{aligned} \frac{dC}{dt} &= -k_{12}C + k_{21}C_{\text{per}} - k_e C + k_a \frac{DF}{V} \sum_{n=0}^{\lfloor t/\tau \rfloor} e^{-k_a(t-n\tau)}, \\ \frac{dC_{\text{per}}}{dt} &= k_{12}C - k_{21}C_{\text{per}}, \end{aligned}$$

37 where $C(t)$ and C_{per} denote the respective concentrations at time $t \geq 0$ in the
 38 central and peripheral compartments, k_{12} denotes the transfer rate from the central
 39 central to peripheral compartment, k_{21} denotes the transfer rate from the peripheral
 40 to central compartment, and k_a , k_e , D , F , V , and τ are as in section S.1.1. The
 41 tirzepatide PK parameter values from [2] are given in Table S.1.

42 S.1.3 Semaglutide PD

43 Our semaglutide PD model and parameters are taken directly from [1]. The
 44 one modification is that we use a time-dependent drug concentration rather
 45 than the weekly average concentration used in [1], but we show in section S.1.5
 46 below that this choice negligibly affects our results.

47 The body weight at time $t \geq 0$ after the start of treatment is

$$W(t) = W_0(1 - E_{\text{pl}}(t) - E_{\text{fast}}(t) - E_{\text{slow}}(t)),$$

48 where W_0 denotes the body weight at the start of treatment and $E_{\text{pl}}(t)$, $E_{\text{fast}}(t)$,
 49 and $E_{\text{slow}}(t)$ denote the dimensionless placebo, fast, and slow drug effects, re-
 50 spectively. The percentage change in body weight from the drug is thus equal
 51 to

$$\frac{W(t) - W_0}{W_0} = -(E_{\text{pl}}(t) + E_{\text{fast}}(t) + E_{\text{slow}}(t)).$$

52 Following Strathe et al. [1], the placebo effect is the sum of a transient
 53 placebo effect and a slow placebo effect,

$$E_{\text{pl}}(t) = E_{\text{pl,tr}}(t) + E_{\text{pl,slow}}(t),$$

54 which evolve according to the following ordinary differential equations (ODEs),

$$\begin{aligned} \frac{dE_{\text{pl,tr}}}{dt} &= k_{\text{pl,tr}}(K_{\text{pl,tr}}e^{-\gamma_{\text{pl,tr}}t} - E_{\text{pl,tr}}), \\ \frac{dE_{\text{pl,slow}}}{dt} &= k_{\text{pl,slow}}(E_{\text{pl,slow},\infty} - E_{\text{pl,slow}}). \end{aligned}$$

55 We note that we were able to obtain similar results by omitting the transient
 56 placebo effect (i.e. setting $E_{\text{pl,tr}}(t) = 0$ for all t), but we retain the transient
 57 placebo effect to be consistent with [1]. The fast and slow drug effects satisfy

$$\begin{aligned} \frac{dE_{\text{fast}}}{dt} &= k_{\text{fast}} \left(\frac{E_{\text{max,fast}}C(t)}{\text{EC}_{50,\text{fast}} + C(t)} - E_{\text{fast}} \right), \\ \frac{dE_{\text{slow}}}{dt} &= k_{\text{slow}} \left(\frac{E_{\text{max,slow}}C(t)}{\text{EC}_{50,\text{slow}} + C(t)} - E_{\text{slow}} \right), \end{aligned}$$

58 where $C(t)$ is the drug concentration obtained from the PK model in sec-
 59 tion S.1.1 (the drug mass is converted to moles using the molar mass μ). Fol-
 60 lowing [1], we set $k_{\text{out,fast}} = \infty$ so that E_{fast} is given by

$$E_{\text{fast}}(t) = \frac{E_{\text{max,fast}}C(t)}{\text{EC}_{50,\text{fast}} + C(t)}.$$

61 It is straightforward to solve these ODEs to obtain

$$\begin{aligned} E_{\text{pl,tr}}(t) &= K_{\text{pl,tr}}k_{\text{pl,tr}} \int_0^t e^{-k_{\text{pl,tr}}(t-s)} e^{-\gamma_{\text{pl,tr}}s} ds, \\ E_{\text{pl,slow}}(t) &= E_{\text{pl,slow},\infty}(1 - e^{-k_{\text{pl,slow}}t}), \\ E_{\text{slow}}(t) &= k_{\text{slow}} \int_0^t e^{-k_{\text{pl,tr}}(t-s)} \frac{E_{\text{max,slow}}C(s)}{\text{EC}_{50,\text{slow}} + C(s)} ds, \end{aligned}$$

Symbol	Description	Semaglutide	Tirzepatide
D	dose amount	2.4 mg [1]	2.5–15 mg [3]
k_a	PK absorption rate	4.973/wk [1]	6.266/wk [2]
k_e	PK elimination rate	0.678/wk [1]	3.090/wk [2]*
V/F	apparent volume of distribution	12.1 L [1]	3.08 L [2]
τ	dosing interval	varied	varied
k_{12}	central to peripheral rate	-	11.836/wk [2]*
k_{21}	peripheral to central rate	-	7.345/wk [2]*
μ	molar mass	4114/gmol [4]	4814/gmol [5]
$k_{pl,tr}$	rate for transient placebo effect	0.00885/wk [1]	0.00620/wk
$K_{pl,tr}$	placebo effect magnitude	34.4% [1]	34.1%
$\gamma_{pl,tr}$	transient placebo decay rate	0.0794/wk [1]	0.2702/wk
$k_{pl,slow}$	rate for slow placebo effect	0.0319/wk [1]	0.0975/wk
$E_{pl,slow,\infty}$	steady-state slow placebo effect	1% [1]	2.19%
$E_{max,fast}$	maximum fast effect	4.19%**	2.59%
$EC_{50,fast}$	half-max. conc. for fast effect	48 nM [1]	45.68 nM
k_{slow}	rate for slow effect	0.0319/wk [1]	0.0364/wk
$E_{max,slow}$	maximum slow effect	22.6%**	27.6%
$EC_{50,slow}$	half-max. conc. for slow effect	48 nM [1]	112.89 nM

Table S.1: Semaglutide and tirzepatide model parameters. The first 8 rows give PK parameters and the final 10 rows give PD parameters. Parameter values with an asterisk (*) were scaled allometrically [6], meaning that the parameter value reported in [2] was multiplied by the factor $(104.8/70)^{0.8}$, which converts a parameter for a 70 kg body weight [2] to one for a 104.8 kg body weight [3]. Tirzepatide PD parameters were estimated in this study. See section S.1.3.1 for details on the values of $E_{max,fast}$ and $E_{max,slow}$ for semaglutide (marked by **).

62 where we have assumed zero initial conditions,

$$E_{pl,tr}(0) = E_{pl,slow}(0) = E_{fast}(0) = E_{slow}(0) = 0,$$

63 which reflects that the therapy starts at time $t = 0$. Parameter values are given
64 in Table S.1.

65 S.1.3.1 Semaglutide E_{max} values

66 The parameters $E_{max,fast}$ and $E_{max,slow}$ were not reported in Strathe et al. [1]
67 for a single “average” patient. Rather, the following values are reported for one
68 specific patient demographic and health profile,

$$E_{max,fast} = 3.99\%, \quad E_{max,slow} = 26.2\%,$$

69 and then it was specified how these parameters vary for different demographic
70 or health characteristics.




Figure S.1: Solid curves are the semaglutide PD model. Markers are clinical trial data from Wilding et al. [7].

71 For our model, we choose the following parameter values,

$$E_{\max,\text{fast}} = 4.19\%, \quad E_{\max,\text{slow}} = 22.6\%. \quad (\text{S.2})$$

72 We chose the values in Equation (S.2) to fit data from Wilding et al. [7], which
 73 was also fit by Strathe et al. [1] (see Figure 2A in [1]). Our resulting fit is shown
 74 in Figure S.1. The values in Equation (S.2) thus describe an average patient
 75 without any prior knowledge of their demographics (i.e. age, sex, etc.).

76 To show that our main conclusions are insensitive to the specific values of
 77 $E_{\max,\text{fast}}$ and $E_{\max,\text{slow}}$, in Figure S.2 we plot the weight loss efficacy relative
 78 to once-weekly dosing against the cost relative to once-weekly dosing for less
 79 frequent dosing (in particular, for dosing intervals of length 7, 8, ..., 28 days).
 80 This plot assumes that cost is proportional to the dose frequency. This plot
 81 shows these curves for letting $E_{\max,\text{fast}}$ and $E_{\max,\text{slow}}$ vary from the values in
 82 Equation S.2. In particular, the various multicolored curves in Figure S.2 cor-
 83 respond to setting

$$E_{\max,\text{fast}} = \phi 4.19\%, \quad E_{\max,\text{slow}} = \psi 22.6\%,$$

84 where the factors ϕ and ψ take the following 11 different values,

$$\phi \in \{0.5, 0.6, \dots, 1.4, 1.5\}, \quad \psi \in \{0.5, 0.6, \dots, 1.4, 1.5\}.$$

85 The key feature of Figure S.2 is that the $11 \times 11 = 121$ multicolored solid
 86 curves are very near each other. Hence, our main conclusion that reducing dose
 87 frequency does not commensurately reduce weight loss efficacy holds regardless




Figure S.2: Reducing cost by reducing dose frequency does not commensurately reduce weight loss efficacy for a wide range of values of the parameters $E_{\max,\text{fast}}$ and $E_{\max,\text{slow}}$. See section S.1.3.1 for details.

88 of the exact values of $E_{\max,\text{fast}}$ and $E_{\max,\text{slow}}$. For instance, notice that all the
 89 multicolored curves in Figure S.2 predict that a patient who switches from a 7
 90 day dosing interval to a 14 day dosing interval maintains between 71% to 75%
 91 of their weight loss, even though their relative dosing frequency (and thus cost)
 92 is cut in half.

93 S.1.4 Tirzepatide PD

94 We model the PD of tirzepatide using the semaglutide PD model in section S.1.3
 95 after reparameterizing the model to fit the data in [3]. The drug concentration
 96 $C(t)$ used in the tirzepatide PD model is obtained from the PK model in sec-
 97 tion S.1.2.

98 S.1.5 Semaglutide average versus time-dependent concen- 99 tration

100 The semaglutide PKPD model that we employ in this paper (detailed above in
 101 sections S.1.1 and S.1.3) is identical to the model of Strathe et al. [1], except
 102 for one minor modification. In our model, the time-dependent semaglutide con-
 103 centration, $C(t)$, is used in the PD model. In [1], the semaglutide concentration
 104 used in the PD model is an average of the prior week (which we denote by
 105 C_{avg}). However, this minor modification only negligibly affects the PD model.
 106 We demonstrate this point in Figure S.3, which shows the percent change in




Figure S.3: Percent change in body weight over time for 2.4 mg once weekly dose of semaglutide. The curves are the semaglutide model in section S.1.3 using either the time-dependent semaglutide concentration C (red solid curve) or the weekly averaged semaglutide concentration C_{avg} (blue dashed curve).

107 body weight for each version of the model. Indeed, other than small oscillations,
 108 the two curves are nearly indistinguishable.

109 S.2 BMI and mortality calculations

110 To obtain BMI estimates, we first estimated the current US adult BMI distribution
 111 from Figure 2 in [8]. Let $p(x)$ denote the probability density function
 112 of this current US adult BMI distribution. If a fraction f of obese US adults
 113 reduces their BMI by a factor of a (where obesity means a BMI of at least 30
 114 kg/m^2), then the resulting BMI distribution has probability density function

$$\bar{p}(x) = \begin{cases} p_0(x) & \text{if } x < 30a, \\ p_0(x) + (f/a)p_0(x/a) & \text{if } 30a \leq x < 30, \\ (1-f)p_0(x) + (f/a)p_0(x/a) & \text{if } x \geq 30. \end{cases} \quad (\text{S.3})$$

115 Here x measures BMI in units of kg/m^2 and $0 \leq f \leq 1$ and $0 < a < 1$. To
 116 understand (S.3) in words, notice that the distribution is unchanged if $x < 30a$,
 117 since (i) adults with BMI less than 30 do not have their BMI reduced (i.e. the
 118 weight-loss treatment is only applied to adults with BMI at least 30) and (ii)
 119 the treatment cannot cause a person to have BMI less than $30a$. Further, the
 120 number of adults with BMI between $30a$ and 30 increases because some obese

121 adults decreased their BMI to a level between $30a$ and 30 . Finally, for a BMI
122 $x \geq 30$, the distribution changes due to both (a) a decrease since some adults
123 who had a BMI of x reduced their BMI and (b) an increase since some adults
124 with a larger BMI (namely, x/a) reduced their BMI to x .

125 The fraction f_1 of obese US adults that can receive q1wk dosing for a given
126 annual supply of semaglutide was computed according to

$$f_1 = \frac{(\text{mg of semaglutide annual supply})}{(2.4 \text{ mg per week})(52 \text{ weeks})(\text{number of obese US adults})},$$

127 where the number of obese US adults was set to 1.066×10^8 [8]. The fraction
128 f_2 that can receive q2wk dosing was set to $f_2 = 2f_1$ where $0 < f_1 \leq 0.5$. The
129 results in the paper were computed from (S.3) with either $a = 1 - 0.19 = 0.81$
130 and $f = f_1$ for q1wk dosing or $a = 1 - 0.14 = 0.86$ and $f = f_2 = 2f_1$ for q2wk
131 dosing.

132 To estimate the number of lives saved, we first estimated the number of
133 annual deaths by multiplying the number of adults in each of the standard
134 seven BMI categories (using the standard BMI cutoffs between categories of
135 18.5, 25, 27.5, 30, 35, and 40) by the BMI category-dependent annual mortality
136 rates reported in [8]. The number of lives saved was then obtained by comparing
137 each hypothetical scenario (i.e. for each distribution \bar{p} in (S.3)) to the current
138 scenario.

139 References

- 140 [1] Anders Strathe, Deborah B Horn, Malte Selch Larsen, Domenica Rubino,
141 Rasmus Sørrig, Marie Thi Dao Tran, Sean Wharton, and Rune Viig Over-
142 gaard. A model-based approach to predict individual weight loss with
143 semaglutide in people with overweight or obesity. *Diabetes, Obesity and*
144 *Metabolism*, 25(11):3171–3180, 2023.
- 145 [2] U.S. Food and Drug Administration. Clinical Pharmacology Review: NDA
146 215866, 2022. Accessed: November 6, 2024.
- 147 [3] Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad, Sean Wharton, Lisa
148 Connery, Breno Alves, Arihiro Kiyosue, Shuyu Zhang, Bing Liu, Mathijs C
149 Bunck, et al. Tirzepatide once weekly for the treatment of obesity. *New*
150 *England Journal of Medicine*, 387(3):205–216, 2022.
- 151 [4] National Center for Biotechnology Information. Pubchem compound sum-
152 mary for CID56843331, semaglutide, 2024. Retrieved September 17, 2024.
- 153 [5] National Center for Biotechnology Information. Pubchem compound sum-
154 mary for CID11977456, tirzepatide, 2024. Retrieved September 17, 2024.
- 155 [6] European Medicines Agency. EPAR assessment report: Mounjaro (h-c-
156 005620-ii-0007), 2024. Accessed: November 6, 2024.

- 157 [7] John PH Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies,
158 Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock,
159 Marie TD Tran, Thomas A Wadden, et al. Once-weekly semaglutide in
160 adults with overweight or obesity. *New England Journal of Medicine*,
161 384(11):989–1002, 2021.
- 162 [8] Abhishek Pandey, Yang Ye, Chad R Wells, Burton H Singer, and Ali-
163 son P Galvani. Estimating the lives that could be saved by expanded ac-
164 cess to weight-loss drugs. *Proceedings of the National Academy of Sciences*,
165 121(43):e2412872121, 2024.